Adaptimmune Therapeutics plc

ADAP • Biotechnology

$0.05

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2025

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$12.81M

Crecimiento

—

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Crecimiento positivo de ingresos · 124.5%Liquidez saludable · 2.92Nivel de deuda alto · 6.26Rentabilidad débil

Datos financieros hasta: 30 jun 2025, 12:00 a.m. UTCÚltima actualización de earnings: 13 ago 2025, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.05

Change0.00%

Shares Out264.09M

Market Cap$12.81M

Enterprise Value$16.94M

52W Range0.02 - 0.86

Beta2.49

P/E-0.08

P/S0.20

P/B-0.18

P/FCF-0.07

EV/Sales0.26

Price$0.05

Change0.00%

Shares Out264.09M

Market Cap$12.81M

Enterprise Value$16.94M

52W Range0.02 - 0.86

Beta2.49

P/E-0.08

P/S0.20

P/B-0.18

P/FCF-0.07

EV/Sales0.26

EV/EBITDA-0.11

EV/FCF-0.09

Dividend Yield0.00%

Gross Margin99.96%

Oper. Margin-38.62%

Profit Margin-39.78%

Debt/Eq6.26

Current Ratio2.92

Quick Ratio2.80

Target$2.83

Target Upside5735.05%

Target Median$3.00

Target Range1.00 - 4.00

Volume1.68M

Avg Volume110.64M

EPS Surprise0.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

58/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

58/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 124.5%Liquidez saludable · 2.92Nivel de deuda alto · 6.26Rentabilidad débil

Analyst view

Analyst sentiment and price target

ADAP

Analyst sentiment

Based on 16 analyst votes · 2026-09-05

69/100

Neutral

Bullish

Hold

Bearish

Precio objetivo

2026-06-06

Bajo

$1.00

Promedio

$2.83

Mediana

$3.00

Alto

$4.00

Resumen de la compañía

IPO: 5/6/2015

Industria: Biotechnology

P/B i: -0.18

Deuda / Patrimonio i: 6.26

Margen operativo: -38.62%

Margen neto: -39.78%

ROE i: -

ROIC: -

Salud financiera

Puntaje12 / 20

Deuda / Patrimonio: 6.26

Ratio corriente: 2.92

Ratio rápido: 2.80

Estado: Good

Advertencias

High debt level

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Fuente - Link

Competidores

ANL APLM BLRX ERNA GOVX LNAI LPCN MBRX OSRH THAR

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Agreement to Improve Treatment Access for People Living with HIV. Agreement will help state ADAP programs provide access to IDVYNSO.

Business Wire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2025-11-12	-0.09	-0.07	0.02
2025-08-13	-0.15	-0.11	0.04
2025-05-13	-0.18	-0.18	0
2025-03-24	-0.17	-0.26	-0.09
2024-11-13	-0.17	-0.07	0.1
2024-08-12	-0.07	0.24	0.31
2024-05-15	-0.16	-0.18	-0.02
2024-03-06	-0.12	-0.24	-0.12
2023-11-08	-0.2	-0.2	0
2023-08-09	-0.17	-0.21	-0.04
2023-05-12	-0.19	0.01	0.2
2023-03-06	-0.25	-0.18	0.07